Dear All, Integrating perspectives from EC HERA, EMA, Health Canada, Norway, UK MHRA, US FDA, and US NIH, the Transatlantic Task Force on AMR (TATFAR)’s

Dear All, On 26 Nov 2026, the Antimicrobial Resistance Surveillance & Research Initiative (AMRSRN) of the Indian Council on Medical Research (ICMR) released its report on

Dear All, Recently posted, six concepts were approved for FY 2027 funding at the September 2025 meeting of NIAID’s Division of Microbiology and Infectious Diseases (DMID). These are

Dear All, I’ve written in the past about the creative work done by the Milken Institute on health care financing (26 Mar 2022 newsletter, “Pull

Dear All, I wrote in the 4 Oct 2025 newsletter about WHO’s updated reviews of antibacterial therapeutics and diagnostics. Team WHO have now released dashboard versions of

Dear All, When I wrote earlier this year (23 Jan 2025 newsletter) that the January 2025 PACCARB meeting (Presidential Advisory Council on Combatting Antimicrobial Resistant

Dear All, I wrote previously (23 Sep 2025 newsletter, “EU’s €253 million, 10-year One Health AMR (OHAMR) Initiative”) about OHAMR (European Partnership on One Health AMR

Dear All, Earlier this year (20 Apr 2025 newsletter), Vivli announced their 2025 AMR Surveillance Data Challenge. Funded by Johnson & Johnson, Paratek, Pfizer and